Ind-Swift Laboratories liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
9.36×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.83×3.83×3.92×2.99×3.14×
3.25×3.25×3.41×2.94×1.96×
38544246743218.2
761722645440793
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDSWFTLAB₹409.80

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,559 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————9.36
Current Ratio3.142.993.923.833.83
Quick Ratio1.962.943.413.253.25
Cash, Equiv & ST Investments18.2431.9467.4441.8385.4
Working Capital793.4439.9644.8722.1760.6
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.